Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2024-04-19 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
灵康药业集团股份有限公司董事会审计委员会对会计师事务所履职评价报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee evaluating the performance of the external audit firm for the fiscal year 2023. It discusses the audit firm's qualifications, the audit process, communication with management, and the audit committee's oversight and evaluation of the audit work. The document references the 2023 annual audit and the issuance of the audit report but does not contain the full annual report or financial statements itself. It is a standalone audit-related report focusing on the audit firm's performance and the audit committee's supervision, which fits the definition of an Audit Report / Information (AR). The document length is 2194 characters, which is relatively short but contains substantive content about the audit process and evaluation, not merely an announcement or certification. Therefore, it should be classified as AR rather than RPA or RNS. FY 2023
2024-04-19 Chinese
2023年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2023 年度内部控制评价报告' which translates to '2023 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2023, including financial and non-financial internal control defects, their identification standards, and remediation status. The document is detailed and contains substantive information about internal control evaluation, which is typically part of audit-related disclosures. It is not an annual report (10-K) or earnings release, nor is it a brief announcement or certification. The content aligns with an Audit Report / Information filing, as it focuses on internal control evaluation and audit opinions related to internal controls. The document length is 4099 characters, which is sufficient for a standalone internal control evaluation report rather than a mere announcement. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2023
2024-04-19 Chinese
灵康药业集团股份有限公司董事会关于独立董事2023年度独立性情况评估专项报告
Governance Information Classification · 95% confidence The document is a special report from the board of directors regarding the independence self-assessment of independent directors for the year 2023. It references regulatory requirements from the China Securities Regulatory Commission and the Shanghai Stock Exchange. The content focuses on governance and compliance related to board members' independence, without financial data or broader management discussion. It is not an annual report, audit report, or earnings release. It fits best under Governance Information (CGR) as it details governance practices and board independence assessments.
2024-04-19 Chinese
中信证券股份有限公司关于灵康药业集团股份有限公司使用部分暂时闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a formal opinion from a sponsoring institution (中信证券股份有限公司) regarding the use of temporarily idle raised funds by 灵康药业集团股份有限公司 for cash management. It references regulatory approvals, board and supervisory committee resolutions, and compliance with securities regulations. The document is a verification or audit opinion on the use of funds rather than a full financial report or earnings release. It does not contain financial statements or detailed financial data but rather an audit or review opinion on a specific financial management activity. The document length is about 2,422 characters, which is relatively short and focused on a specific regulatory compliance matter. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to regulatory compliance, excluding full annual or interim reports. Q1 2024
2024-04-19 Chinese
灵康药业集团股份有限公司2023年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm for the year 2023, specifically assessing the audit firm Zhongshen Zhonghuan's work on the company's 2023 financial and internal control audits. It discusses the audit firm's qualifications, the audit process, and the company's evaluation of the audit firm's performance. The document contains no actual financial statements or detailed financial data but rather an assessment of the audit firm's duties and independence. This matches the description of an Audit Report / Information (AR) filing, which includes standalone audit reports and evaluations of audit firms' performance, excluding full annual reports. The document length is 1553 characters, which is short but contains substantive content about the audit firm's work, not just an announcement or certification. Therefore, the correct classification is AR with high confidence. FY 2023
2024-04-19 Chinese
独立董事专门会议议事规则
Governance Information Classification · 100% confidence The document is titled '独立董事专门会议议事规则' which translates to 'Rules of Procedure for Independent Directors' Special Meetings' of Lingkang Pharmaceutical Group Co., Ltd. It details governance rules, meeting procedures, voting, and responsibilities of independent directors. There is no financial data, no mention of financial results, no regulatory filings or announcements, no voting results, no capital changes, no legal proceedings, and no presentation or report publication. The content focuses on internal governance structure and board procedures, specifically related to independent directors' meetings. This fits the definition of Governance Information (CGR), which covers the company's internal rules, board structure, and governance practices.
2024-04-19 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.